CN111295375B - 制备大尺寸异噁唑啉粒子的方法 - Google Patents

制备大尺寸异噁唑啉粒子的方法 Download PDF

Info

Publication number
CN111295375B
CN111295375B CN201880071993.8A CN201880071993A CN111295375B CN 111295375 B CN111295375 B CN 111295375B CN 201880071993 A CN201880071993 A CN 201880071993A CN 111295375 B CN111295375 B CN 111295375B
Authority
CN
China
Prior art keywords
lana
lei
fluorine
particles
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880071993.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111295375A (zh
Inventor
G.X.周
A.科特
L.R.申克
A.科诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of CN111295375A publication Critical patent/CN111295375A/zh
Application granted granted Critical
Publication of CN111295375B publication Critical patent/CN111295375B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Insects & Arthropods (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
CN201880071993.8A 2017-11-07 2018-11-06 制备大尺寸异噁唑啉粒子的方法 Active CN111295375B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762582381P 2017-11-07 2017-11-07
US62/582381 2017-11-07
US201762608904P 2017-12-21 2017-12-21
US62/608904 2017-12-21
PCT/EP2018/080230 WO2019091940A1 (en) 2017-11-07 2018-11-06 Process for preparing large size isoxazoline particles

Publications (2)

Publication Number Publication Date
CN111295375A CN111295375A (zh) 2020-06-16
CN111295375B true CN111295375B (zh) 2025-06-24

Family

ID=64172503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880071993.8A Active CN111295375B (zh) 2017-11-07 2018-11-06 制备大尺寸异噁唑啉粒子的方法

Country Status (16)

Country Link
US (2) US11858904B2 (enExample)
EP (1) EP3707129A1 (enExample)
JP (3) JP7446222B2 (enExample)
KR (2) KR102819993B1 (enExample)
CN (1) CN111295375B (enExample)
AU (2) AU2018363686B2 (enExample)
BR (1) BR112020008848A2 (enExample)
CA (1) CA3081653A1 (enExample)
CL (1) CL2020001172A1 (enExample)
CO (1) CO2020006258A2 (enExample)
IL (1) IL274075A (enExample)
MX (3) MX2020004693A (enExample)
PE (1) PE20210170A1 (enExample)
PH (1) PH12020500586A1 (enExample)
UA (1) UA127892C2 (enExample)
WO (1) WO2019091940A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081646C (en) 2017-11-07 2024-03-19 Intervet International B.V. Injectable isoxazoline pharmaceutical compositions and uses thereof
MX2022007455A (es) 2019-12-18 2022-08-15 Elanco Tiergesundheit Ag Derivados de isoxazolina como plaguicidas.
AU2021277491B2 (en) 2020-05-20 2024-05-16 Intervet International B.V. Injectable pharmaceutical compositions and uses thereof
KR20230043904A (ko) 2020-07-24 2023-03-31 엘랑코 유에스 인코포레이티드 이속사졸린 화합물 및 이의 중간체의 제조 공정
CN112724095A (zh) * 2020-09-25 2021-04-30 安徽省公众检验研究院有限公司 氟雷拉钠晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102947278A (zh) * 2010-05-27 2013-02-27 杜邦公司 4-[5-[3-氯-5-(三氟甲基)苯基]-4,5-二氢-5-(三氟甲基)-3-异*唑基]-n-[2-氧代-2-[(2,2,2-三氟乙基)氨基]乙基]-1-萘甲酰胺的晶形
CN103800324A (zh) * 2012-11-01 2014-05-21 住友化学株式会社 向狗施用防治体外寄生虫的药剂的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4883296B2 (ja) 2004-03-05 2012-02-22 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
MX2009013748A (es) 2007-06-27 2010-01-26 Du Pont Metodo de control de plagas en animales.
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
WO2009063910A1 (ja) 2007-11-12 2009-05-22 Nissan Chemical Industries, Ltd. 光学活性イソキサゾリン化合物の触媒的不斉合成方法
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
CA2973871C (en) * 2008-07-09 2019-09-10 Nissan Chemical Industries, Ltd. Production method of isoxazoline-substituted benzoic acid amide compound
ES2442342T3 (es) 2008-12-18 2014-02-11 Novartis Ag Derivados de las isoxazolinas y su uso como pesticida
BRPI0923009B1 (pt) 2008-12-19 2018-07-17 Elanco Tiergesundheit Ag compostos de isoxazolina, composição para o controle de parasitas e uso de compostos de isoxazolina para o preparo de composição para o controle de parasitas
CA2766291C (en) * 2009-06-24 2016-06-21 Msd Oss B.V. Injectable formulations containing asenapine and method of treatment using same
JP5679102B2 (ja) 2009-08-03 2015-03-04 日産化学工業株式会社 ジヒドロイソキサゾール置換安息香酸化合物の光学活性体とジアステレオマー塩及びその製造方法
TWI487486B (zh) 2009-12-01 2015-06-11 Syngenta Participations Ag 以異唑啉衍生物為主之殺蟲化合物
DE102010003711B4 (de) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
WO2014126208A1 (ja) 2013-02-14 2014-08-21 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物の結晶性多形体及びその製造方法
JP2015028006A (ja) 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法
LT3052080T (lt) 2013-09-30 2025-08-25 Zoetis Services Llc Ilgo veikimo spiro-izoksazolino vaistinės formos
PL3082867T3 (pl) * 2013-12-20 2024-05-13 Intervet International B.V. Kompozycje izoksazoliny i ich zastosowanie w zapobieganiu lub leczeniu inwazji pasożytów u zwierząt
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
US20170020848A1 (en) 2015-04-08 2017-01-26 Merial Inc. Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
CA3081646C (en) 2017-11-07 2024-03-19 Intervet International B.V. Injectable isoxazoline pharmaceutical compositions and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102947278A (zh) * 2010-05-27 2013-02-27 杜邦公司 4-[5-[3-氯-5-(三氟甲基)苯基]-4,5-二氢-5-(三氟甲基)-3-异*唑基]-n-[2-氧代-2-[(2,2,2-三氟乙基)氨基]乙基]-1-萘甲酰胺的晶形
CN103800324A (zh) * 2012-11-01 2014-05-21 住友化学株式会社 向狗施用防治体外寄生虫的药剂的方法

Also Published As

Publication number Publication date
KR20200085295A (ko) 2020-07-14
JP2021501755A (ja) 2021-01-21
US20240246921A1 (en) 2024-07-25
AU2024201160A1 (en) 2024-03-14
AU2018363686A1 (en) 2020-05-07
KR20240125076A (ko) 2024-08-19
JP2023099059A (ja) 2023-07-11
MX2025006001A (es) 2025-07-01
NZ765172A (en) 2024-05-31
JP2024010042A (ja) 2024-01-23
RU2020117583A3 (enExample) 2021-12-24
KR102819993B1 (ko) 2025-06-11
BR112020008848A2 (pt) 2020-10-20
EP3707129A1 (en) 2020-09-16
CO2020006258A2 (es) 2020-05-29
AU2018363686B2 (en) 2023-11-23
CL2020001172A1 (es) 2020-10-23
JP7446222B2 (ja) 2024-03-08
US20200331867A1 (en) 2020-10-22
IL274075A (en) 2020-06-30
CA3081653A1 (en) 2019-05-16
PH12020500586A1 (en) 2021-06-21
CN111295375A (zh) 2020-06-16
JP7578752B2 (ja) 2024-11-06
PE20210170A1 (es) 2021-01-29
RU2020117583A (ru) 2021-12-08
MX2023014279A (es) 2024-07-10
US11858904B2 (en) 2024-01-02
MX2020004693A (es) 2020-08-20
WO2019091940A1 (en) 2019-05-16
KR102694519B1 (ko) 2024-08-13
UA127892C2 (uk) 2024-02-07

Similar Documents

Publication Publication Date Title
CN111295375B (zh) 制备大尺寸异噁唑啉粒子的方法
KR20060006949A (ko) 반용매 고화 방법
JP2002518495A (ja) イルベサルタンの新規なフォーム、それを得る方法およびそれを含む医薬組成物
CN105367515A (zh) 一种氢溴酸沃替西汀α晶型的制备方法
JP2024010042A5 (enExample)
Stieger et al. Recrystallization of active pharmaceutical ingredients
RU2006121341A (ru) Кристаллические формы дигидрохлорида (6r)-l-эритро-тетрагидробиоптерина
JP2010511589A (ja) 静的条件下における溶液中の結晶成長
RU2797561C2 (ru) Способ получения частиц изоксазолина большого размера
KR101573616B1 (ko) 구아닐우레아 디니트라미드의 재결정에 의한 형상 및 입도 조절방법
CN105439980A (zh) 一种氢溴酸沃替西汀一仲丁醇合物及其制备方法
CN113278016B (zh) 一种小粒径阿齐沙坦的制备方法
US20150225380A1 (en) Novel Method to Obtain Olmesartan Medoxomil With Reduced Particle Size
KR20040000783A (ko) 직접 접촉 냉각 결정화법을 이용한 헥사나이트로스틸벤의재결정화 방법
NZ805055A (en) Process for preparing large size isoxazoline particles
CN117263875A (zh) 一种戊唑醇晶体及其连续结晶方法和应用
KR102833486B1 (ko) 디하이드록실암모늄 5,5'-비스테트라졸-1,1'-디올레이트 재결정화 방법 및 그에 의해 재결정화된 tkx-50
KR20210088879A (ko) Hniw 재결정화 방법
AU4030101A (en) Anhydrous mirtazapine and process for preparing the same
Rietveld et al. Navigating phase behaviour in pharmaceuticals to enable phases with desired properties
JP2019532942A (ja) 有機化合物を結晶化させるための界面活性剤系
JP7486763B2 (ja) 安定なアジルサルタン微細結晶の製造方法
NZ765172B2 (en) Process for preparing large size isoxazoline particles
WO2017071375A1 (zh) 一种氘代咪唑酮化合物的晶型及其制备方法和用途
CN117026361A (zh) 一种在水溶液中培养5,5'-联四唑-1,1'二氧羟铵盐毫米级大晶体的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant